CB Therapeutics Announces Closing of the Latest Round of Equity Funding for Scaling Up Biosynthesis Research and Production

SAN DIEGO–(BUSINESS WIRE)–CB
Therapeutics, an innovative biotechnology company focusing on
research and production of wellness compounds, announced the closing of
the first round of equity funding for its research projects. The company
raised $7.5 M to establish world-class research facilities in the
Southern California region and assemble an impressive scientific team.

“We are excited to announce this milestone,” said Sher Ali Butt, CEO and
co-founder of CB Therapeutics. “With the establishment of our labs in
the Southern California area, we are poised to accelerate our research
efforts and address the ever-growing demand for our services from
entities in the U.S. and abroad. We are appreciative and encouraged from
the support we’ve received from our partners and we are looking forward
to implementing the next steps of our growth strategy.”

About CB Therapeutics

CB Therapeutics utilizes sustainable microorganisms and its proprietary
biotechnology platform to produce therapeutic compounds found in nature.
Through biosynthesis, CB Therapeutics has produced various rare
compounds that have not been previously available due to the difficulty
producing them and the cost inefficiencies in extracting them from
nature.

Contacts

Sher Ali Butt
[email protected]